JP6543370B2 - 嗅覚機能を改善する医薬組成物 - Google Patents
嗅覚機能を改善する医薬組成物 Download PDFInfo
- Publication number
- JP6543370B2 JP6543370B2 JP2018037080A JP2018037080A JP6543370B2 JP 6543370 B2 JP6543370 B2 JP 6543370B2 JP 2018037080 A JP2018037080 A JP 2018037080A JP 2018037080 A JP2018037080 A JP 2018037080A JP 6543370 B2 JP6543370 B2 JP 6543370B2
- Authority
- JP
- Japan
- Prior art keywords
- olfactory
- pharmaceutical composition
- chitosan
- composition according
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2271—Neuropeptide Y
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims (12)
- 嗅覚機能を改善する医薬組成物において、
該医薬組成物は糖質を有効成分として含み、且つ該糖質は、ヘパラン硫酸プロテオグリカン、アミノ糖、N−アシル化アミノ糖、キチン類(chitin−based)物質からなる群から選択される、或いは、それらを組み合せたものであることを特徴とする嗅覚機能を改善する医薬組成物。 - 前記キチン類物質はキトサン、キトサンオリゴ糖、もしくはその水溶性誘導体であることを特徴とする請求項1記載の医薬組成物。
- 前記アミノ糖は、グルコサミンであることを特徴とする請求項1記載の医薬組成物。
- 前記N−アシル化アミノ糖は、N−アセチルグルコサミン、N−アセチルガラクトサミン、N−アセチルマンノサミンからなる群から選択される、或いは、それらを組み合せたものであることを特徴とする請求項1記載の医薬組成物。
- 前記医薬組成物により改善する嗅覚機能が、嗅神経上皮再生を促進、嗅覚受容体ニューロン分化を促進、シグナル伝達タンパクを増加、からなる群から選択される、或いは、それらを組み合せたものであることを特徴とする請求項1記載の医薬組成物。
- 前記シグナル伝達タンパクが、嗅覚ニューロン特異プロテインG(olfactory neuron specific−G protein,Golf)、アデニル酸シクラーゼ・タイプ3(adenylate cyclase type 3,ADCY3)からなる群から選択される、或いは、それらを組み合わせたものであることを特徴とする請求項5記載の医薬組成物。
- 前記医薬組成物は、更に呼吸上皮再生又は繊毛成長を促進する、或いは、それら組み合わせて促進することを特徴とする請求項1記載の医薬組成物。
- ヒアルロン酸を更に含み、該ヒアルロン酸は前記糖質と組み合わせて用いられることを特徴とする請求項1記載の医薬組成物。
- 前記糖質は、キトサンであることを特徴とする請求項8記載の医薬組成物。
- 前記医薬組成物は、溶液であることを特徴とする請求項1記載の医薬組成物。
- 前記医薬組成物中に占める前記糖質の含有量が、0.001wt%以上であることを特徴とする請求項1記載の医薬組成物。
- 前記医薬組成物が、鼻腔内局部に投薬方式で必要な個体に投与するのに用いられることを特徴とする請求項1記載の医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW106134150 | 2017-10-03 | ||
TW106134150A TWI633888B (zh) | 2017-10-03 | 2017-10-03 | 醣類物質用於製備改善嗅覺功能的藥物之用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019064996A JP2019064996A (ja) | 2019-04-25 |
JP6543370B2 true JP6543370B2 (ja) | 2019-07-10 |
Family
ID=64452626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018037080A Active JP6543370B2 (ja) | 2017-10-03 | 2018-03-02 | 嗅覚機能を改善する医薬組成物 |
Country Status (3)
Country | Link |
---|---|
US (1) | US10507216B2 (ja) |
JP (1) | JP6543370B2 (ja) |
TW (1) | TWI633888B (ja) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6410046B1 (en) * | 1996-11-19 | 2002-06-25 | Intrabrain International Nv | Administering pharmaceuticals to the mammalian central nervous system |
US9439925B2 (en) * | 2010-04-06 | 2016-09-13 | Synedgen, Inc. | Methods and compositions for treating wounds utilizing chitosan compounds |
-
2017
- 2017-10-03 TW TW106134150A patent/TWI633888B/zh active
-
2018
- 2018-03-02 JP JP2018037080A patent/JP6543370B2/ja active Active
- 2018-04-02 US US15/943,400 patent/US10507216B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20190099440A1 (en) | 2019-04-04 |
US10507216B2 (en) | 2019-12-17 |
TW201914594A (zh) | 2019-04-16 |
JP2019064996A (ja) | 2019-04-25 |
TWI633888B (zh) | 2018-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020200603B2 (en) | Compositions and methods of use thereof | |
US20070197471A1 (en) | Treatment of degenerative cartilage conditions in a mammal with Glycosidasc Inhibitors | |
Schreurs et al. | Tissue engineering strategies combining molecular targets against inflammation and fibrosis, and umbilical cord blood stem cells to improve hampered muscle and skin regeneration following cleft repair | |
US10195226B2 (en) | Medicinal carbohydrates for treatment of respiratory conditions | |
JP6543370B2 (ja) | 嗅覚機能を改善する医薬組成物 | |
US20230172994A1 (en) | Methods of promoting vasculogenesis | |
CN114053251A (zh) | 硫酸化多糖吸入制剂及其在防治新冠病毒相关疾病中的应用 | |
JP5679582B2 (ja) | 線維性障害を処置する方法 | |
US11197885B2 (en) | Collagen enhancing agent made from low acyl gellan gum, methods of making and methods of using the same | |
CN115209954B (zh) | 用于治疗呼吸系统病变的组合物 | |
WO2020147350A1 (zh) | 阿拉伯木聚糖磺酸盐在制备治疗骨关节炎的药物中的应用 | |
WO2021236626A1 (en) | Mucoretentive antiviral technologies | |
Cheng et al. | A new function of a previously isolated compound that stimulates activation and differentiation of myogenic precursor cells leading to efficient myofiber regeneration and muscle repair | |
JP2013147480A (ja) | 医薬組成物及びこれを用いた薬用化粧品 | |
EP3578184A1 (en) | Resorption enhancers as additives to improve the oral formulation of low molecular weight heparins | |
JP4463510B2 (ja) | グリア瘢痕形成抑制剤 | |
IL143279A (en) | Use of low molecular weight heparin for the preparation of pharmaceutical preparations for the treatment of motoneuronic diseases | |
US20230181610A1 (en) | Methods and Compositions for Treatment of Cystic Fibrosis Class I Mutations | |
JP5756498B2 (ja) | 変形性関節症予防治療薬 | |
US20230122776A1 (en) | Antiviral agent | |
CN116870010A (zh) | Azd3965在制备预防/治疗视网膜前膜产生的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190131 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190610 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190614 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6543370 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |